Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C
Abstract
Aim of investigation. To estimate relation of polymorphism of genes encoding reninangiotensin system components (AGT G-6A, AGT M235T and ATR1 A1166C) with rate of liver fibrosis progression in patients with chronic hepatitis C (CHC).
Material and methods. Overall 109 patients with CHC and liver cirrhosis C with established stage of fibrosis and duration of disease have been divided into group of «rapidly progressing fibrosis» (55 patients, ≥0,130 fibrosis points/year) and «slowly progressing fibrosis» (54 persons, <0,130 fibrosis units/year). Assessment of polymorphism of studied genes was carried out by molecular genetic methods.
Results. In CHC patients of «rapidly progressing fibrosis» group in comparison to «slowly progressing fibrosis» group minor A-allele (50,0 and 33,3% respectively, p=0,0126) and «mutant» АА-genotype (27,3 and 11,1%, р=0,0324; OR АА=3,00; 95% CI 1,07-8,45), AGT gene on locus G-6A, as well as minor T-allele (р=0,0407) of AGT gene in M235T locus were significantly more common while MM genotype of M235T polymorphism of AGT gene (20,8 and 44,4%, respectively, p=0,0090; OR MM=0,33; 95%-CI 0,15–0,73) were significant less frequent. No significant differences between groups in distribution of alternative alleles and genotypes of ATR1 gene on A1166C locus have been revealed.
Conclusion. Carriage of mutant alleles of angiotensinogen gene on any of loci (G-6A or M235T) is the factor predicting more rapid progression of disease. As chronic hepatitis C is multifactorial disease, it is rational to use testing of allelic variants of angiotensinogen gene in patient-specific approach at CHC management.
About the Authors
O. V. Taratina
Lomonosov Moscow state university
Russian Federation
Russian Federation
T. N. Krasnova
Lomonosov Moscow state university; State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
L. M. Samokhodskaya
Lomonosov Moscow state university
Russian Federation
Russian Federation
T. N. Lopatkina
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. A. Tkachuk
Lomonosov Moscow state university
Russian Federation
Russian Federation
N. A. Mukhin
Lomonosov Moscow state university; State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Абдуллаев С.М., Целищева Ю.И., Самоходская Л.М. и др. Генетические маркеры предрасположенности к агрессивному течению хронического гепатита С // Вестн. РАМН. — 2007.— № 1. — C. 8–13.
2. Ивашкин В.Т., Павлов Ч.С. Фиброз печени. — М.: ГЭОТАР-Медиа, 2011. — 168 с.
3. Кучерявый Ю.А., Стукова Н.Ю., Ахтаева М.Л. Хронический гепатит, цирроз печени и гепатоцеллюлярная карцинома — звенья одной цепи // Клин. перспективы гастроэнтерол. гепатол. — 2012.— № 5. — C. 3–11.
4. Лопаткина Т.Н., Кудлинский И.С. Роль полиморфизмов гена интерлейкина 28В в оценке эффективности противовирусной терапии хронического гепатита С // Клин. гепатол. — 2011.— № 2. — C.
5. –38.
6. Рекомендации по диагностике и лечению взрослых больных гепатитом С. // Рос. журн. гастроэнтерол. гепатол. колопроктол. — 2013. — T. 23, № 2. — C. 41–70.
7. Самоходская Л.М., Балацкий А.В., Садекова О.Н. и др. Молекулярно-генетический анализ предрасположенности человека к мультифакторным заболеваниям / Под ред. Ткачука В.А. — М.: Изд-во Моск. ун-та, 2011. — 388 с.
8. Самоходская Л.М., Игнатова Т.М., Абдуллаев С.М. и др. Прогностическое значение комбинации аллельных вариантов генов цитокинов и гемохроматоза у больных хроническим гепатитом С // Рос. журн. гастроэнтерол. гепатол. колопроктол. — 2007. — T. 17, № 2. — C. 50–56.
9. Таратина О.В., Краснова Т.Н., Самоходская Л.М. и др. Полиморфизм генов эндотелиальной дисфункции и скорость прогрессирования фиброза печени при хроническом гепатите С // Тер. арх. — 2014.— № 4 (в печати).
10. Тихонова Н.Ю., Бурневич Э.З. Новые возможности прогнозирования ответа на противовирусную терапию хронического гепатита С // Фарматека. — 2012.— № 2. — C. 32–35.
11. Altarescu G., Haim S., Elstein D. Angiotensinogen promoter and angiotensinogen II receptor type 1 gene polymorphisms and incidence of ischemic stroke and neurologic phenotype in Fabry disease // Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals.— 2013. — Vol. 18, N. 7. — P. 595–600.
12. Asselah T., Bieche I., Paradis V. et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C // Semin. Liver Dis.— 2007. — Vol. 27, N 1. — P. 13–27.
13. Bataller R., Sancho-Bru P., Gines P. et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II // Gastroenterology.— 2003. — Vol. 125, N 1. — P. 117–125.
14. Bataller R., Gines P., Nicolas J. M. et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells // Gastroenterology.— 2000. — Vol. 118, N 6. — P. 1149–1156.
15. Bataller R.., Sancho-Bru P., Gines P. et al. Liver fibrogenesis: a new role for the renin-angiotensin system // Antioxid Redox Signal.— 2005. — Vol. 7, N 9–10. — P. 1346–1355.
16. Bataller R.., Schwabe R.F., Choi Y.H. et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis // J. Clin. Invest.— 2003. — Vol. 112, N 9. — P. 1383–1394.
17. Brenner D.A. Molecular pathogenesis of liver fibrosis // Trans. Am. Clin. Climatol. Assoc.— 2009. — Vol. 120. — C. 361–368.
18. Cariani E., Villa E., Rota C. et al. Translating pharmacogenetics into clinical practice: interleukin (IL) 28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection // Clinical chemistry and laboratory medicine: CCLM // FESCC.— 2011. — Vol. 49, N 8. — P. 1247–1256.
19. Clark P.J., Thompson A.J., McHutchison J.G. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies // Am. J. Gastroenterol.— 2011. — Vol. 106, N 1. — P. 38–45.
20. Fabris C., Toniutto P., Bitetto D. et al. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile // Liver Int.— 2005. — Vol. 25, N 6. — P. 1128–1135.
21. Fattovich G., Covolo L., Bibert S. et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C // Aliment. Pharmacol. Ther.— 2011. — Vol. 33, N 10. — P. 1162–1172.
22. Forrest E.H., Thorburn D., Spence E. et al. Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection // J. Viral. Hepat.—2005. — Vol. 12, N 5. — P. 519–524.
23. Friedman S.L. Evolving challenges in hepatic fibrosis // Nat. Rev. Gastroenterol. Hepatol.— 2010. — Vol. 7, N 8. — P. 425–436.
24. Girgrah N., Liu P., Collier J. et al. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis // Gut.— 2000. — Vol. 46, N 1. — P. 114–120.
25. Hsu C.C., Bray M.S., Kao W.H. et al. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study // J. Am. Soc. Nephrol.: JASN.—2006. — Vol. 17, N 2. — P. 504–512.
26. Huang H., Shiffman M.L., Friedman S. et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C // Hepatology.—2007. — Vol. 46, N 2. — P. 297–306.
27. Inoue I., Nakajima T., Williams C.S. et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro // J. Clin. Invest.— 1997. — Vol. 99, N 7. — P. 1786–1797.
28. Jeunemaitre X. Genetics of the human renin angiotensin system // J. Mol. Med.— 2008. — Vol. 86, N 6. — P. 637–641.
29. Jonsson J.R., Clouston A.D., Ando Y. et al. Angiotensinconverting enzyme inhibition attenuates the progression of rat hepatic fibrosis // Gastroenterology.— 2001. — Vol. 121, N 1. — P. 148–155.
30. Kanno K., Tazuma S., Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl (4) // Biochem Biophys. Res. Commun.— 2003. — Vol. 308, N 1. — P. 177–183.
31. Lee J.K., Hsieh J.F., Tsai S.C. et al. Effects of single dose of 50 mg captopril in patients with liver cirrhosis and ascites // Hepatogastroenterology.— 2000. — Vol. 47, N 33. — P. 767–770.
32. Lubel J.S., Herath C.B., Tchongue J. et al. Angiotensin(1–7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat // Clin. Sci. (Lond.).— 2009. — Vol. 117, N 11. — P. 375–386.
33. Nabeshima Y., Tazuma S., Kanno K. et al. Deletion of angiotensin II type I receptor reduces hepatic steatosis // J. Hepatol.— 2009. — Vol. 50, N 6. — P. 1226–1235.
34. Nguyen Dinh Cat A., Touyz R. M. A new look at the renin-angiotensin system-focusing on the vascular system // Peptides.— 2011. — Vol. 32, N 10. — P. 2141–2150.
35. Ochi H., Maekawa T., Abe H. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients // Gastroenterology.— 2010. — Vol. 139, N 4. — P. 1190–1197.
36. Paizis G., Tikellis C., Cooper M.E. et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2 // Gut.— 2005. — Vol. 54, N 12. — P. 1790–1796.
37. Powell E.E., Edwards-Smith C.J., Hay J.L. et al. Host genetic factors influence disease progression in chronic hepatitis C // Hepatology.— 2000. — Vol. 31, N 4. — P. 828–833.
38. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups // Lancet.— 1997. — Vol. 349, N
39. — P. 825–832.
40. Richardson M.M., Powell E.E., Barrie H.D. et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C // J Med Genet.— 2005. — Vol. 42, N 7. — e45.
41. Sookoian S., Castano G., Garcia S.I. et al. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension // Am. J. Gastroenterol.— 2005. — Vol. 100, N 3. — P. 636–642.
42. Strader D.B., Wright T., Thomas D.L. et al. Diagnosis, management, and treatment of hepatitis C // Hepatology.— 2004. — Vol. 39, N. 4. — P. 1147–1171.
43. Wang J.H., Lin C.M., Wang L. S. et al. Association between molecular variants of the angiotensinogen gene and hypertension in Amis tribes of eastern Taiwan // J. Formosan Med. Assoc. = Taiwan yi zhi.— 2002. — Vol. 101, N 3. — P. 183–188.
44. Xiao F., Wei H., Song S. et al. Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B // J. Gastroenterol. Hepatol.— 2006. — Vol. 21, N 9. — P. 1488–1491.
45. Yang L., Bataller R., Dulyx J. et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice // J. Hepatol.— 2005. — Vol. 43, N 2. — P. 317–323.
46. Yoshiji H., Kuriyama S., Yoshii J. et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats // Hepatology.— 2001. — Vol. 34, N 4 Pt 1. — P. 745–750.
Review
For citations:
Taratina O.V., Krasnova T.N., Samokhodskaya L.M., Lopatkina T.N., Tkachuk V.A., Mukhin N.A. Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(2):69-77. (In Russ.)
Views:
79
Email this article 
